WebAstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk Dec 12, 2024 01:01pm Clovis Oncology finally throws in the towel,... WebFeb 16, 2024 · In late 2024, Biogen Inc. reportedly began drafting plans to get rid of more than 1,000 positions, by way of layoffs, attrition and leaving open positions unfilled. While the company never...
Struggling with Alzheimer
WebMay 7, 2024 · EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease. June 23, 2024. News Release. WebApr 12, 2024 · Report Shows Expected Uptick in Layoffs and Collaboration across BioPharma. 3/13/2024. A recent report released by accounting and consulting firm BDO … Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT … Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in … Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical … Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple … Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug … Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited … Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales … ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap … FDA Commissioner and Chief Scientist Announce Decision to Withdraw … KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated … cygwin with python
In a sudden move, Biogen
WebMar 3, 2024 · John Tlumacki/The Boston Globe via Getty. After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million. … WebMar 3, 2024 · Mar 3, 2024. Biogen Inc. has begun eliminating positions as part of a long-promised cost-saving measure in the wake of the fallout from its Alzheimer's drug. The … WebDec 11, 2024 · The June approval of Biogen's (NASDAQ:BIIB) Aduhelm (aducanumab) was touted as the one of the biggest in years, yet the company's stock is down 5% year … cygwin workflow management